Karyopharm Therapeutics (NASDAQ:KPTI) Earns Buy Rating from HC Wainwright

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $7.00 target price on the stock.

A number of other analysts have also commented on KPTI. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Piper Sandler increased their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Karyopharm Therapeutics Price Performance

KPTI opened at $0.60 on Thursday. Karyopharm Therapeutics has a 1 year low of $0.53 and a 1 year high of $1.70. The business has a fifty day simple moving average of $0.67 and a 200 day simple moving average of $0.76. The company has a market capitalization of $75.71 million, a PE ratio of -0.53 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. Equities analysts anticipate that Karyopharm Therapeutics will post -0.83 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Velan Capital Investment Management LP bought a new position in Karyopharm Therapeutics during the fourth quarter valued at approximately $27,000. Two Sigma Advisers LP lifted its holdings in Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after buying an additional 45,400 shares during the period. Two Sigma Investments LP boosted its holdings in Karyopharm Therapeutics by 60.3% in the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock valued at $93,000 after acquiring an additional 51,856 shares in the last quarter. Shay Capital LLC purchased a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at about $116,000. Finally, Focus Partners Wealth bought a new position in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).